Clinical trials: CDA
Lymphocytic Leukemia, Chronic
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
This study will assess the effect of maintenance treatment with rituximab in comparison with observation period (no treatment), in participants with progressive B-cell CLL who have had previous first-line induction treatment with…
- Trial name
- NCT00718549
- Testing
- Cladribine, Cyclophosphamide, Rituximab
- Where
- 6 sites in Belarus, Poland
- Volunteers
- 128 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)
The goal of this study was to evaluate the safety, tolerability and effectiveness of oral cladribine when taken in combination with Interferon-beta (IFN-beta) therapy for the treatment of multiple sclerosis (MS).
- Trial name
- ONWARD (NCT00436826)
- Testing
- Cladribine, Interferon-beta (IFN-beta)
- Where
- 39 sites in United States, Italy and 2 more
- Volunteers
- 172 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Multiple Sclerosis
A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)
To evaluate the effectiveness, patient-reported outcomes (PROs) and safety of cladribine tablets in participants with relapsing forms of multiple sclerosis (RMS) including relapsing-remitting multiple sclerosis (RRMS) and active…
- Trial name
- NCT03933215
- Testing
- Cladribine
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Malaria, Falciparum
Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria
CDA is a combination of chlorproguanil, dapsone and artesunate, being developed in a public-private partnership with the Medicines for Malaria Venture (MMV), World Health Organisation (WHO-TDR) and academic partners from the…
- Trial name
- NCT00371735
- Testing
- chlorproguanil-dapsone-artesunate, chlorproguanil-dapsone
- Where
- 7 sites in Burkina Faso, Ghana and 2 more
- Volunteers
- 900 people
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
This study aims to describe participants characteristics that can predict the safety and effectiveness of cladribine tablets, as assessed by time-to-discontinuation of treatment with cladribine tablets, and to assess other…
- Trial name
- NCT05797740
- Testing
- Mavenclad
- Where
- 30 sites in Belgium, Czechia and 4 more
- Volunteers
- 366 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany